AMLX

$22.48-$0.87 (-3.73%)live

Compare

Held by

portfolios on TandT

Bookmarked by

users

Avg position size

—

of holders' portfolios

13F filers

institution

Market cap

$2.6B

111M shares

52-week range

$7.63 – $24.60

88% from low

Sector

PHARMACEUTICAL PREPARATIONS

Exchange

NASDAQ

Change+$4.41

Analyst estimates (consensus)

Year	Est. revenue	Growth	Est. EPS	EPS range	Fwd P/E	# Analysts
2026	$80625	-99.9%	$-1.47	$-1.67–$-1.33	—	5
2027	$32M	+39643.6%	$-1.35	$-1.81–$-0.96	—	6
2028	$131M	+308.4%	$-0.72	$-0.87–$-0.48	—	4
2029	$369M	+182.4%	$0.94	$0.07–$2.78	23.8×	1

Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep

Earnings surprises

Beat consensus in 3 of the last 8 reported quarters

Reported	Est. EPS	Actual	Surprise
2026-08-06	$-0.36	$-0.39	-8.1%
2026-05-07	$-0.34	$-0.37	-8.8%
2026-03-03	$-0.31	$-0.30	+3.2%
2025-11-06	$-0.43	$-0.37	+14.0%
2025-08-07	$-0.44	$-0.46	-4.5%
2025-05-08	$-0.45	$-0.42	+6.7%
2025-03-04	$-0.49	$-0.55	-12.2%
2024-11-07	$-0.47

DCF fair valuemodel estimate

Intrinsic value

$2.30

Price

$22.48

Implied downside

-90%

Peer comparison

Symbol	Price	Today	Mkt cap	P/E
AMLXAmylyx Pharmaceuticals, Inc.	$22.48	-3.73%	$2.5B	—
ATAIAtai Beckley Inc.	$7.25	+0.28%	$2.7B	—
CVACCureVac N.V.	$4.66	+0.00%	$1.0B	—
IMTXImmatics N.V.	$9.59	-1.24%	$1.3B	—
INBXInhibrx Biosciences Inc.	$97.01	-1.37%

Amylyx Pharmaceuticals, Inc. Common Stock

Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases.

www.amylyx.com

Employees: 136
IPO / List date: Jan 7, 2022
HQ: CAMBRIDGE, MA

Held by traders on TradeandTell

No one on the platform currently holds AMLX.

Super investors & insiders

Institutions holding (13F)

Institution	Shares	Reported
Renaissance Technologiesas of 2025-12-31	192,500	$2.3M

Insider activity (SEC Form 4)

Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.

Insider activity (SEC Form 4)

Recent trades on TradeandTell

No one on the platform has traded AMLX yet.

$AMLX chatter on StockTwits

Iyot@Monkey777919249m
$AMLX PT on good or bad data? They have others in pipeline dont they?
View on StockTwits ↗
Jason Worthy@buyoutorbust_5h
$AMLX Being realistic, where do you guys see the share price post-data if it meets its endpoint?
View on StockTwits ↗
Sam@LoveRetailFrothBullish1d
$AMLX 🤔 feverish accumulation ☕️ $40
View on StockTwits ↗
PRISM MarketView@prismmarketview2d
We are adding Amylyx Pharmaceuticals (NASDAQ: $AMLX ) to the PRISM Emerging Pharmaceuticals Index. Amylyx has completed the last participant visit in the 16-week double-blind portion of its pivotal Phase 3 LUCIDITY trial of avexitide in post-bariatric hypoglycemia, with topline data expected in late August or early September. There are no FDA-approved therapies for PBH, and the company estimates the condition affects roughly 160,000 people in the U.S. Management says NDA sections are being prepared now and a field medical affairs team is already deployed. A dedicated ICD-10 code for PBH takes effect October 1. Amylyx reports a cash runway into 2028, which the company expects to carry it through a potential 2027 launch if avexitide is approved. We are tracking AMLX because the readout is close, the indication is uncontested, and they provide exposure to a first-in-class opportunity in an underserved metabolic condition. https://prismmarketview.com/companies/amylyx-pharmaceuticals-inc/ #AmylyxPharmaceuticals
View on StockTwits ↗
aj@ajmoreBullish3d
$AMLX "MBX ran an independent experiment → got results strongly consistent with avexitide → gained additional confidence that GLP-1 antagonism works in PBH → then decided not to spend years competing against an already Phase-3 asset. That last causal step is an inference, not something MBX has publicly admitted. But the clinical read-through itself is genuinely strong.". MBX had indirectly valudated that avexitide works! (hence not worth spending money on their own program).
View on StockTwits ↗
Sam@LoveRetailFrothBullish3d
$AMLX Good Morning ☕️ Endo Orphan market. BUY. https://seekingalpha.com/article/4933147?gt=37096d923a19a3b7
View on StockTwits ↗
aj@ajmoreBullish3d
$AMLX price target raised to 30 (from 22) at BoFA
View on StockTwits ↗
Sam@LoveRetailFroth5d
@swardfishtrader @I0VA Nice to hear you guys. Yeah GTHX was fun . $AMLX will be 15-20X bigger deal but similar. I hope they are putting Cosela to good use. I haven’t checked on them. I remember my wife not able to finish her chemotherapy due to neutropenia. GL
View on StockTwits ↗
aj@ajmoreBullish5d
$AMLX so why are management so positive? and analysts! and patients. takeaways from pbh: 1. its biological: the acarbose and canagliflozin failed trial proved i) acarbose and canagliflozin dont help, and ii) placebo had flat zero impact on reduction of events type 2, 3. -> the placebo group in avexitide trial will not surprise with any benefits compared to the drug, so any reductions in the avexitide group will be sugnificant and again with p<0.01. THIS is IMPORTANT. 2. the fact that ole was well subscribed and the eap offered that means avexitide works. 3. some patients feedback saying avexitide got their life back. very positive here and analysts raising targets at this stage is another good sign.
View on StockTwits ↗
aj@ajmoreBullish6d
$AMLX Bio-Pharma deals are Mondays announcements. After yeaterday's conf call, the odds gone higher.
View on StockTwits ↗
Sam@LoveRetailFrothBullish6d
$RXRX $AMLX Good Morning August ☕️ My Bio 💎 s Over to you $SANA next on Monday! $TEM
View on StockTwits ↗
Sam@LoveRetailFrothBullish6d
$AMLX Just doing some math. It’s mind boggling the value here & the impending Buyout battle. 10X🍺
View on StockTwits ↗
Alex Bishop@abishop717Aug 6
$AMLX looking good here
View on StockTwits ↗
latina queen@Kabita84Aug 6
$AMLX this is one of the all time great bio stock..people must be retired now..
View on StockTwits ↗
aj@ajmoreBullishAug 6
$AMLX I think system running low on shares! 30? keep the momentum.
View on StockTwits ↗

Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.